Kala Bio (KALA) Other Accumulated Expenses (2016 - 2025)
Kala Bio (KALA) posted Other Accumulated Expenses of $104000.0 for Q4 2025, up 57.58% sequentially from $66000.0 in Q3 2025, and down 74.82% YoY from $413000.0 in Q4 2024.
Kala Bio (KALA) Other Accumulated Expenses (2016 - 2025) Analysis & Trends
Kala Bio has reported Other Accumulated Expenses for 10 years, with the latest figure at $104000.0 in Q4 2025.
- Quarterly Other Accumulated Expenses fell 74.82% year-over-year to $104000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $104000.0 (down 74.82% YoY) and the FY2025 annual result came in at $104000.0, down 74.82% from the prior year.
- Other Accumulated Expenses rose to $104000.0 in Q4 2025 per KALA's latest filing, from $66000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $824000.0 in Q4 2021 and troughed at $66000.0 in Q3 2025.
- A 5-year average of $461357.1 and a median of $452500.0 in 2022 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2021 and 2025: Other Accumulated Expenses surged 205.56% in 2021, then slumped 74.82% in 2025.
- Over 5 years, Other Accumulated Expenses stood at $824000.0 in 2021, then sank by 50.61% to $407000.0 in 2022, then decreased by 6.63% to $380000.0 in 2023, then rose by 8.68% to $413000.0 in 2024, then plunged by 74.82% to $104000.0 in 2025.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $104000.0, $66000.0, and $436000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Kala Bio | 9.89 Mn | 9.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 104,000.00 |
| Sep 30, 2025 | 66,000.00 |
| Jun 30, 2025 | 436,000.00 |
| Dec 31, 2024 | 413,000.00 |
| Dec 31, 2023 | 380,000.00 |
| Mar 31, 2023 | 777,000.00 |
| Dec 31, 2022 | 407,000.00 |
| Sep 30, 2022 | 422,000.00 |
| Jun 30, 2022 | 469,000.00 |
| Mar 31, 2022 | 534,000.00 |
| Dec 31, 2021 | 824,000.00 |
| Sep 30, 2021 | 554,000.00 |
| Jun 30, 2021 | 550,000.00 |
| Mar 31, 2021 | 523,000.00 |
| Dec 31, 2020 | 552,000.00 |
| Sep 30, 2020 | 620,000.00 |
| Jun 30, 2020 | 180,000.00 |
| Mar 31, 2020 | 465,000.00 |
| Dec 31, 2019 | 1.03 Mn |
| Sep 30, 2019 | 463,000.00 |